345 related articles for article (PubMed ID: 35713074)
1. Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
Kalra S; Bhattacharya S; Kapoor N
J Pak Med Assoc; 2022 May; 72(5):989-990. PubMed ID: 35713074
[TBL] [Abstract][Full Text] [Related]
2. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kobayashi K; Toyoda M; Hatori N; Sakai H; Furuki T; Chin K; Kimura M; Saito N; Kanaoka T; Aoyama T; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Machimura H; Hishiki T; Umezawa S; Shimura H; Nakajima S; Yamamoto H; Sato K; Miyakawa M; Terauchi Y; Tamura K; Kanamori A
Diabetes Res Clin Pract; 2022 Mar; 185():109231. PubMed ID: 35131376
[TBL] [Abstract][Full Text] [Related]
3. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.
Luo J; Feldman R; Rothenberger S; Korytkowski M; Fischer MA; Gellad WF
J Gen Intern Med; 2022 Nov; 37(14):3562-3569. PubMed ID: 35048301
[TBL] [Abstract][Full Text] [Related]
5. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J
Eur J Clin Pharmacol; 2023 Sep; 79(9):1239-1248. PubMed ID: 37449993
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
[No Abstract] [Full Text] [Related]
7. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
Gao Y; Peterson E; Pagidipati N
Am Heart J; 2020 Jun; 224():47-53. PubMed ID: 32304879
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
[TBL] [Abstract][Full Text] [Related]
10. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chen WJ
Diabetologia; 2022 Dec; 65(12):2032-2043. PubMed ID: 35945333
[TBL] [Abstract][Full Text] [Related]
11. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
[TBL] [Abstract][Full Text] [Related]
12. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment.
Consoli A; Formoso G; Baldassarre MPA; Febo F
Expert Opin Drug Saf; 2018 Mar; 17(3):293-302. PubMed ID: 29334278
[TBL] [Abstract][Full Text] [Related]
13. Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus.
Kim CH; Hwang IC; Choi HM; Ahn CH; Yoon YE; Cho GY
Int J Cardiol; 2022 Oct; 364():104-111. PubMed ID: 35716949
[TBL] [Abstract][Full Text] [Related]
14. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
Lim S; Kim KM; Nauck MA
Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
[TBL] [Abstract][Full Text] [Related]
17. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile.
Muzurović E; Mikhailidis DP
Expert Opin Pharmacother; 2020 Dec; 21(17):2125-2135. PubMed ID: 32697112
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes.
Limonte CP; Hall YN; Trikudanathan S; Tuttle KR; Hirsch IB; de Boer IH; Zelnick LR
J Diabetes Complications; 2022 Jun; 36(6):108204. PubMed ID: 35537891
[TBL] [Abstract][Full Text] [Related]
19. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization.
Shepard BD; Ecelbarger CM
Semin Nephrol; 2021 Jul; 41(4):331-348. PubMed ID: 34715963
[TBL] [Abstract][Full Text] [Related]
20. Macrovascular Complications.
McRae M; Low Wang CC
Prim Care; 2022 Jun; 49(2):255-273. PubMed ID: 35595481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
